Geranyl acetate is a floral-fruity monoterpene ester that softens and sweetens many rosy, neroli, petitgrain, coriander, ylang-ylang, and palmarosa profiles. Live sources strongly support its identity, ester chemistry, and repeated natural occurrence in essential oils, while the biological literature is more limited and less mature than the geraniol record. Public data do include isolated preclinical findings in antifungal, antioxidant, antinociceptive, and keratinocyte inflammation models, plus older FAO/WHO flavor-safety evaluations and modern regulatory listings. For AromaForge, geranyl acetate is best framed as a chemistry-forward aroma constituent with emerging standalone preclinical data and safety context that partly overlaps with geraniol because ester hydrolysis can matter.
Chemical identity and composition
NIST and PubChem identify geranyl acetate as the acetate ester of geraniol with formula C12H20O2. Because SCCS notes that substances transformed by hydrolysis to known contact allergens should be treated as equivalent examples in safety reasoning, geranyl acetate deserves cautious allergen-context handling even though the ester itself is typically discussed more as an odorant and flavor material than as a primary sensitizer.
Aroma and practical use
- Use the recorded floral, rose-like, fruity, green, waxy descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2010 Candida study found geranyl acetate fungicidal at 0.064% v/v, active against dimorphism, and able to lower fluconazole MIC in a resistant Candida albicans strain.
The PubMed abstract reports equal efficacy to geraniol at the tested MIC, 99.9% kill within 30 minutes, and a 32-fold reduction of fluconazole MIC in a resistant strain.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2013 experimental-model paper reported antinociceptive and some antioxidant effects for geranyl acetate in vivo and in vitro systems.
The accessible search result and full-text landing description frame geranyl acetate as one of the tested monoterpenes with measurable antinociceptive and redox effects, but this remains preclinical and not disease-specific evidence.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2025 HaCaT keratinocyte paper reported that geranyl acetate attenuated para-phenylenediamine-induced cytotoxicity, DNA-damage signaling, apoptosis markers, and inflammatory cytokine expression.
The abstract reports lower p53/MAPK, STAT3, and NF-kB signaling along with reductions in IL-1alpha, IL-1beta, IL-6, TNF-alpha, IL-24, and multiple chemokines.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedHistorical FAO/WHO toxicology data and later WHO/JECFA specification records support geranyl acetate as an established flavoring material with defined identity and review history.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
SCCS indicates that geraniol and its esters should be considered relevant in allergen communication when transformation back to the known allergen is plausible.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Most standalone efficacy-style findings for geranyl acetate remain preclinical, so archive copy should keep benefits language cautious and non-medical.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
suppression of inflammatory signaling in keratinocyte stress models
A 2025 HaCaT-cell study reported reduced phosphorylation of p53, MAPK, STAT3, and NF-kB p65 with lower cytokine and chemokine output after geranyl acetate co-treatment.
This experimental finding does not establish benefit, dose or safety in people using this blend.
direct antifungal and fluconazole-sensitizing activity against Candida
A Candida paper found geranyl acetate fungicidal at tested MIC levels and able to lower fluconazole MIC in a resistant strain, suggesting direct microbiologic activity rather than only mixture effects.
This experimental finding does not establish benefit, dose or safety in people using this blend.
ester hydrolysis relevance to allergen handling
Safety review logic from SCCS treats geraniol esters as relevant because hydrolysis can regenerate a known fragrance allergen even when the ester is evaluated primarily for odor or flavor use.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- This pass did not verify a constituent-specific modern RIFM PDF for geranyl acetate itself, although public JECFA and related regulatory records are available.
- Standalone human clinical data for isolated geranyl acetate were not verified in the reviewed public sources.
- Some positive literature remains assay-level or cell-model evidence rather than robust translational data.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.